EMA’s CHMP recommends Sotyktu for plaque psoriasis

BMS’s Sotyktu was the only new therapy that made it onto the list of positive recommendations by EMA’s CHMP in January. The agency recommended new indications for seven approved medicines, and adopted a negative opinion on Sohonos.

Sotyktu deucravacitinib from Bristol Myers Squibb Co. (NYSE:BMY) was recommended for moderate-to-severe plaque psoriasis. In September, Sotyktu became the first TYK2 inhibitor to be approved in the U.S., and an EC approval would make it the first in the EU as well...